Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.

Cardiovasc Ther · 2016 · PMC5108443 · PMID 26990595

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Urine Urinary cGMP levels showed a trend toward an increase by Day 7 and were significantly increased by Day 21; urinary ANP levels significantly increased by the end of each treatment period (Table 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.